Relugolix Use in Transgender Women
Relugolix is not established or recommended for use in transgender women based on current evidence and guidelines. The available guidelines and FDA labeling do not support its use in this population, and there are established, evidence-based alternatives with known safety profiles.
Current Standard of Care
The Endocrine Society guidelines recommend GnRH agonists (not antagonists like relugolix) for testosterone suppression in transgender women, specifically in adolescents for pubertal suppression 1. For adult transgender women, the standard approach involves:
- Estrogen therapy as the primary feminizing agent
- Adjunctive antiandrogens to suppress testosterone to female range (<55 ng/dL)
- Established options include: spironolactone, cyproterone acetate, or GnRH agonists (such as goserelin acetate) 1
The 2009 Endocrine Society guidelines specifically mention that GnRH agonist goserelin acetate in combination with estrogen was effective in reducing testosterone levels with low incidence of adverse reactions in 60 MTF transgender persons 1. More recent literature confirms that gonadotropin-releasing hormone agents are among the most popular adjunctive androgen-lowering agents 2.
Why Relugolix Is Not Recommended
Lack of Evidence in Transgender Population
- FDA approval is exclusively for advanced prostate cancer 3
- All clinical trials studied cisgender men with prostate cancer 4, 5, 6, 7
- No published data exists on safety, efficacy, or appropriate dosing in transgender women
- The mechanism targets castration levels (<50 ng/dL), which is the therapeutic goal, but without transgender-specific validation 3
Practical Concerns
- Relugolix requires daily oral dosing (120 mg after 360 mg loading dose) 3
- Rapid testosterone recovery occurs after discontinuation (55% recovered to >280 ng/dL by 90 days) 3, which could be problematic if adherence lapses
- Cost considerations: Relugolix is significantly more expensive than established alternatives, with cost-effectiveness only demonstrated in prostate cancer populations 7
Safety Profile Unknown in This Context
While relugolix shows reduced cardiovascular events compared to GnRH agonists in prostate cancer patients 6, 7, 8, transgender women have different baseline cardiovascular risk profiles due to estrogen therapy. The interaction between relugolix and feminizing hormone therapy has not been studied 2.
Monitoring Protocol If Used Off-Label
If a clinician considers off-label use despite lack of evidence, adapt the prostate cancer monitoring framework with transgender-specific targets:
Dosing (Extrapolated from Prostate Cancer Data)
Monitoring Schedule
- Testosterone levels: Every 2-3 months initially, then every 3-6 months
- Estradiol levels: Maintain at ~200 pg/mL (premenopausal female range) 1
- Prolactin: Annually (estrogen-related risk) 1
- Liver function tests: Every 3 months first year, then 1-2 times yearly 1
- Cardiovascular risk factors: Blood pressure, lipids, glucose at each visit 1
- Bone density: If risk factors present or age >60 1
Critical Drug Interactions
- Avoid P-gp inhibitors and moderate CYP3A inhibitors: Erythromycin increases relugolix exposure 3.5-fold 3
- Relugolix is a P-gp substrate with only 12% bioavailability 3
Recommended Approach
Use established therapies with proven safety profiles in transgender women:
- First-line: Spironolactone 100-200 mg daily + estradiol (oral, transdermal, or parenteral) 1
- Alternative: Cyproterone acetate (where available) + estradiol 1
- If GnRH suppression needed: GnRH agonist (goserelin, leuprolide) + estradiol 1
Target testosterone <55 ng/dL and estradiol ~200 pg/mL with monitoring every 3 months during first year, then 1-2 times yearly 1.
Common Pitfall
Do not assume that newer agents approved for prostate cancer are automatically appropriate for transgender care. The physiologic context, concurrent estrogen therapy, and treatment goals differ substantially. Stick with evidence-based protocols unless participating in formal research studies.